Scientific Report 2003-2004 - Cleveland Clinic Lerner Research ...
Scientific Report 2003-2004 - Cleveland Clinic Lerner Research ... Scientific Report 2003-2004 - Cleveland Clinic Lerner Research ...
THE YI LABORATORYPOSTDOCTORAL FELLOWSKekke Fan, Ph.D.Jing Li, M.D.TECHNICIANSMingli CaoKundu SumanThe Department of Cancer BiologyPathogenic Role of PTPases in Cancer andAnti-Cancer Activities of PTPase InhibitorsProtein tyrosine phosphatases (PTPases) arekey switches in many important eukaryoticcellular signaling pathways and are tumorsuppressers or anti-oncogenes. Consistent with itsnegative role in signaling, PTPase SHP-1deficiency has been found by us and others incertain human hematopoietic malignancies(polycythemia vera, lymphoma and acuteleukemia) and could be a contributing pathogenicfactor. Certain PTPases may also function asoncogenes. Increased expression of PTPase-alphaand PRLs was associated with late-stage humancolon cancer and caused cell transformation invitro. Amplification of HePTP was detected insome cases of human acute myeloid leukemia.We hypothesize that SHP-1 interacts withand dephosphorylates distinct substrates thatmediate signals of activation,proliferation and differentiation inhematopoietic cells. We have detectedseveral novel SHP-1 substratesinvolved in the growth control ofhematopoietic cells by affinitypurification and mutational analysis.Further characterization of thesesubstrates and determination of theirrole in mitogenic signaling are pivotalin elucidating the mechanisms thatcontrol normal proliferation ofhematopoietic cells. Such efforts will alsoprovide novel insights about the pathogenicprocess of SHP-1 deficiencies in causinghematopoietic diseases.As PTPases play a pivotal role in intracellularsignaling, their inhibitors are expected to havesignificant clinical activities and are targets ofextensive research efforts. Our recent studiesdemonstrated, for the first time, that sodiumstibogluconate is a potent PTPase inhibitor andhas marked anti-cancer activity as a single agentor, more strikingly, in combination with IFNalpha,which is currently used in anti-cancertherapies. Our ongoing studies will furtherexploit its potential as a novel anti-cancer drugand characterize the biologic activities of otherPTPase inhibitors.Taolin Yi, Ph.D.Kant, A.M., De, P., Peng, X., Yi, T., Rawlings, D.J., Kim, J.S., and D.L. Durden (2002) SHP-1 regulatesFcgamma receptor-mediated phagocytosis and the activation of RAC. Blood 100:1852-1859.Yang, W., Tabrizi, M., and T. Yi (2002) A bipartite NLS at the SHP-1 C-terminus mediates cytokineinducedSHP-1 nuclear localization in cell growth control. Blood Cells, Molecules, and Diseases 28:63-74.Joliat, M.J., Lang, P.A., Lyons, B.L., Burzenski, L., Lynes, M.A., Yi, T., Sundberg, J.P., and L.D. Shultz(2002) Absence of CD5 dramatically reduces progression of pulmonary inflammatory lesions in SHP-1protein-tyrosine phosphatase-deficient ‘viable motheaten’ mice. J. Autoimmun. 18:105-117.Pathak, M.K., Hu, X., and T. Yi (2002) Effects of sodium stibogluconate on differentiation and proliferationof human myeloid leukemia cell lines in vitro. Leukemia 16:2285-2291.Yi, T., Pathak, M.K., Lindner, D.J., Ketterer, M.E., Farver, C., and E.C. Borden (2002) Anticanceractivity of sodium stibogluconate in synergy with IFNs. J. Immunol. 169:5978-5985.Pathak, M.K., Dhawan, D., Lindner, D.J., Borden, E.C., Farver, C., and T. Yi (2002) Pentamidine is aninhibitor of PRL phosphatases with anticancer activity. Mol. Cancer Ther. 1:1255-1264.64
CellBiology
- Page 15 and 16: The Department of Biomedical Engine
- Page 17 and 18: The Department of Biomedical Engine
- Page 19 and 20: The Department of Biomedical Engine
- Page 21 and 22: Examples of devices that are being
- Page 23 and 24: The Department of Biomedical Engine
- Page 25 and 26: The Department of Biomedical Engine
- Page 27 and 28: The Department of Biomedical Engine
- Page 29 and 30: The Department of Biomedical Engine
- Page 31 and 32: The Department of Biomedical Engine
- Page 33 and 34: Deep brain stimulation (DBS) of the
- Page 36 and 37: ORTHOPAEDICBIOLOGY ANDBIOENGINEERIN
- Page 38 and 39: ORTHOPAEDICBIOLOGY ANDBIOENGINEERIN
- Page 40 and 41: ORTHOPAEDICBIOLOGY ANDBIOENGINEERIN
- Page 42 and 43: CONNECTIVETISSUEBIOLOGYTHE MIDURALA
- Page 44 and 45: The Department of Biomedical Engine
- Page 46 and 47: DEPARTMENT OFCANCER BIOLOGYCHAIRMAN
- Page 48 and 49: The Department of Cancer Biology46D
- Page 50 and 51: THE ALMASANLABORATORYVISITING SCHOL
- Page 52 and 53: Graham Casey, Ph.D.THE CASEYLABORAT
- Page 54 and 55: THE DANESHGARILABORATORYPOSTDOCTORA
- Page 56 and 57: THE ERZURUMLABORATORYRESEARCH ASSOC
- Page 58 and 59: THE HESTONLABORATORYSTAFF SCIENTIST
- Page 60 and 61: The Department of Cancer BiologyIde
- Page 62 and 63: THE SIZEMORELABORATORYRESEARCH FELL
- Page 64 and 65: THE WILLIAMSLABORATORYPROJECT SCIEN
- Page 68 and 69: DEPARTMENT OFCELL BIOLOGYINTERIM CH
- Page 70 and 71: The Department of Cell BiologyRole
- Page 72 and 73: THE CHISOLMLABORATORYRESEARCH ASSOC
- Page 74 and 75: THE DRISCOLLLABORATORYPOSTDOCTORAL
- Page 76 and 77: THE HAZENLABORATORYRESEARCH ASSOCIA
- Page 78 and 79: The Department of Cell BiologyHyper
- Page 80 and 81: The Department of Cell BiologyRole
- Page 82 and 83: THE J. SMITHLABORATORYTECHNOLOGISTG
- Page 84 and 85: THE WEIMBSLABORATORYPROJECT SCIENTI
- Page 86 and 87: The Department of Cell BiologyCell
- Page 88 and 89: DEPARTMENTOF IMMUNOLOGYCHAIRMANThom
- Page 90 and 91: THE ARONICALABORATORYSENIOR RESEARC
- Page 92 and 93: THE FAIRCHILDLABORATORYPOSTDOCTORAL
- Page 94 and 95: THE HAMILTONLABORATORYPROJECT SCIEN
- Page 96 and 97: THE LARNERLABORATORYPOSTDOCTORAL FE
- Page 98 and 99: THE M. SIEMIONOWLABORATORYRESEARCH
- Page 100 and 101: The Department of ImmunologyHyaluro
- Page 102 and 103: The Department of ImmunologyImmunol
- Page 104 and 105: DEPARTMENT OFMOLECULAR BIOLOGYCHAIR
- Page 106 and 107: THE GUDKOVLABORATORYPROJECT SCIENTI
- Page 108 and 109: THE HARTERLABORATORYPOSTDOCTORAL FE
- Page 110 and 111: THE PADGETTLABORATORYPROJECT SCIENT
- Page 112 and 113: THE G. SENLABORATORYPROJECT SCIENTI
- Page 114 and 115: THE STARKLABORATORYPROJECT SCIENTIS
CellBiology